Aspen posts growth on ex-S. Africa expansion; FDA clears Teva's Jerusalem plant;

@FiercePharma: RT @reutersBenHir: #Novartis talks up Alcon (up to low-double digit growth + $350M synergies) as development head jumps to Gates Foundation. | Follow @FiercePharma

> GlaxoSmithKline ($GSK) partner Aspen Pharmacare posted a 20% increase in full-year profits, as revenues and profits from markets outside South Africa exceeded domestic numbers for the first time. News

> Teva Pharmaceutical Industries said the FDA has cleared its Jerusalem plant, which had been cited in January for manufacturing violations, after a reinspection of the facility. Story

> Medicis Pharmaceutical agreed to sell its technologies unit, which recently won approval for the Liposonix device, to Solta for $15 million. Item

> An analyst hiked sales projections for Optimer Pharmaceuticals' C. difficile treatment Dificid, sending shares up. Article

> GlaxoSmithKline sued Impax Laboratories, which is working toward a knock-off version of GSK's prostate drug Jalyn. News

> Prescription drugs in Australia are among the most expensive in the world, a new study has found. Story

> The Scottish Medicines Consortium approved Celgene's Vidaza for use in patients with advanced myelodysplastic syndromes after the company proposed a patient access scheme. Article

> People who regularly use painkillers similar to ibuprofen and naproxen may be run a higher risk of kidney cancer. Report

> According to a new study, statins appear safe to use after stroke; data suggested use of the drugs does not increase the risk of brain bleeding. News

> Two meta-analyses found that lifestyle changes and statin therapy not only improved cardiovascular risk factors, but also led to better sexual function in men. Item

Biotech News

@FierceBiotech: Novartis hasn't cut R&D spend, unlike some drugmakers. Has logged 17 new drug approvals over the past 1.5 years in U.S., Europe | Follow @FierceBiotech

@JohnCFierce: Dutch biotech AM-Pharma raises €29.2 million in D round. Report | Follow @JohnCFierce

@RyanMFierce: Kiwi firm (not fruit) Biomatters, which sells scientific software, has opened its first U.S. offices in NJ and CA. Item | Follow @RyanMFierce

@MaureenFierce: Pharma hiring on the rise for the fourth quarter in a row. Story | Follow @MaureenFierce

> On a winning streak, Novartis maps bullish ophthalmology R&D strategy. Article 

> Termeer launches cancer research center with $10M in seed cash. Story

Biotech Research News

> From a poisonous crocus, comes an anti-cancer smart bomb. News

> Drugs in search of LTR with right protein. Report

> New obesity drugs will tell the brain that enough is enough. Article 

> Green-glowing cats light the way to possible new AIDS treatment. News

> Embryonic, induced pluripotent stem cells found to be similar. Report 

Manufacturing News

> Survey: Pharma hiring on the rise. Story

> iPad can be lean enabler in hands of execs. Article

> Patheon reveals strategy amid poor financials. Report 

> German trial a step toward upcoming track/trace mandate. News

> Roche tops DJ healthcare sustainability index. Story

And Finally... A small study suggests that an insulin nasal spray may help delay Alzheimer's disease; researchers caution that follow-up is needed. Report

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.